Skye Bioscience, Inc. (SKYE)

OTCMKTS: SKYE · Delayed Price · USD
0.0252
-0.0021 (-7.52%)
Aug 18, 2022 4:00 PM - Market closed
-7.52%
Market Cap 12.50M
Revenue (ttm) n/a
Net Income (ttm) -8.52B
Shares Out 495.93M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 411,814
Open 0.0256
Previous Close 0.0273
Day's Range 0.0252 - 0.0289
52-Week Range 0.0240 - 0.1550
Beta 0.46
Analysts n/a
Price Target n/a
Earnings Date n/a

About SKYE

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed ... [Read more...]

Industry Biotechnology
Founded 2012
CEO Brian Murphy
Employees 9
Stock Exchange OTCMKTS
Ticker Symbol SKYE
Full Company Profile

News

Emerald Health Therapeutics, Inc. Provides Update on and Additional Background to Transaction with Skye Bioscience

Vancouver, British Columbia--(Newsfile Corp. - August 12, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company") is providing an update and additional backgroun...

Skye Bioscience Updates Phase 1 Timeline

San Diego, California, July 20, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivativ...

Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophtha...

Lead drug candidate has shown superior and longer-lasting lowering of intraocular pressure, a risk factor associated with glaucoma, in preclinical studiesSan Diego, California--(Newsfile Corp. - June 30...

Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Gr...

New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system

Skye Bioscience to Present at LD Micro Invitational

San Diego, California--(Newsfile Corp. - June 6, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives...

Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics

Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022

Emerald Health Therapeutics Signs Arrangement Agreement with Skye Bioscience

Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to start later in 2022Preclinical st...

Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate

San Diego, Calif, March 03, 2022 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived mol...

Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study

Initiation of Phase 1 clinical trial of SBI-100 o phthalmic nanoemulsion expected in the second quarter of 2022

Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model

SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules t...

Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD

Skye Bioscience Announces Promotion of Tu Diep, MSc to Chief Development Officer

Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360

SAN DIEGO, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecul...

Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

Exclusive sponsored research agreement with endocannabinoid research pioneers Exclusive sponsored research agreement with endocannabinoid research pioneers

Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

SAN DIEGO, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with si...

Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering

SAN DIEGO, CA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecul...

Skye Bioscience Announces $7.0 Million Registered Direct Offering

SAN DIEGO, CA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecul...

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutic...

SAN DIEGO, CA, Sept. 21, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with s...

Skye Bioscience to Present at the H.C. Wainwright Ophthalmology Conference

SAN DIEGO, CA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseas...

Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies

THCVHS shows no signs of chromosomal or gene mutations in preclinical studies

Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors

SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) --  Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecul...

Cannabis Industry Investor Presentations Now Available for On-Demand Viewing

NEW YORK, July 1, 2021 /PRNewswire/ -- Virtual Investor Conferences® and KCSA Strategic Communications today announced that the presentations from the June 29 th & 30th Cannabis Industry Virtual lnvesto...

Other symbols: ALEAFCLVRIMCCMRMD

Cannabis Industry Investor Conference: Company Executives Present June 29th & 30th

NEW YORK, June 22, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications and ATB Capital Markets today announced the agenda for the upcoming Cannabis Indust...

Other symbols: ALEAFCLVRIMCCMRMD

Skye Bioscience's THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Com...

THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average IOP reduction of 26.5% at 9 hours, significantly better th...

Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program

San Diego, Calif, April 22, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived mole...

Skye Bioscience to Present at Upcoming Investment Conferences in April

San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived mole...